GlassScriptPhysician profile
Walter Butler
NPI 1871603886
$3,899.28
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $585 · 2020: $570 · 2021: $1,174 · 2022: $543 · 2023: $932 · 2024: $93.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,026.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,026.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $492.59 | 2020-2023 | |
| Abbvie INC. | $420.23 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $406.20 | 2019-2023 | Hetlioz, Fanapt |
| Alkermes, INC. | $369.61 | 2019-2024 | Lybalvi |
| Otsuka America Pharmaceutical, INC. | $330.51 | 2019-2023 | Nuedexta |
| Lundbeck LLC | $231.12 | 2019-2023 | Rexulti |
| Allergan, INC. | $190.03 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $189.98 | 2019-2023 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $189.44 | 2019-2024 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $133.19 | 2019-2023 | Austedo Xr, Austedo |
| Tris Pharma INC | $111.32 | 2022-2023 | Dyanavel Xr |
| Neurocrine Biosciences, INC. | $105.40 | 2020 | |
| Corium, LLC | $96.06 | 2023-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $95.50 | 2020-2024 | Jornay Pm |
| Bausch Health US, LLC | $91.30 | 2020-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $85.29 | 2021-2023 | Adzenys Xr-Odt |
| Idorsia Pharmaceuticals US INC | $80.65 | 2023-2024 | Quviviq |
| Noven Therapeutics, LLC | $71.18 | 2023 | Xelstrym, Secuado |
| Shire North American Group INC | $45.08 | 2019 | |
| Axsome Therapeutics, INC. | $41.22 | 2022-2023 | Auvelity |
| Avanir Pharmaceuticals, INC. | $31.36 | 2019-2022 | |
| Eisai INC. | $27.73 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $26.49 | 2020 | |
| Supernus Pharmaceuticals, INC. | $24.10 | 2023 | Qelbree |
| Merck Sharp & Dohme LLC | $13.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Butler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.